stockrowJanux Therapeutics, Inc.
JANX Healthcare Biotechnology
Janux Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.0 million, down 5.55% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- +12.8%
- Free cash flow
- −94.5%
Quarter to September 2026, against a year earlier
Follow JANX
Alert me
Janux Therapeutics, Inc. (JANX) EV/Sales
As of 6 November 2026, Janux Therapeutics, Inc. (JANX) trades at a EV/Sales of 5.0×. Over the past ten years it has ranged from −17.4× (March 2022) to 347× (May 2024); the current reading is higher than 30% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −5.8× | — |
| FY2024 | 175× | 902.87% |
| FY2023 | 17.4× | (40.93%) |
| FY2022 | 29.5× | 20.32% |
| FY2021 | 24.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 4.3× | — |
| Jun 2026 | −0.2× | — |
| Mar 2026 | −6.0× | — |
| Sep 2025 | 27.2× | (84.43%) |
| 16 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ODTX Odyssey Therapeutics, Inc. compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| MLTX MoonLake Immunotherapeutics compare | n/m |
| SPTX Seaport Therapeutics, Inc compare | n/m |
| SVRA Savara Inc. compare | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| JANX Janux Therapeutics, Inc. | 5.0× |
| IMTX Immatics N.V. compare | 12.1× |
| CTY City Therapeutics, Inc compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)